Elicio Therapeutics Inc (ELTX)
9.55
+0.14
(+1.49%)
USD |
NASDAQ |
May 13, 11:47
Elicio Therapeutics Research and Development Expense (Quarterly): 6.157M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 6.157M |
| September 30, 2023 | 7.264M |
| June 30, 2023 | 4.944M |
| December 31, 2022 | 4.29M |
| Date | Value |
|---|---|
| September 30, 2022 | 4.593M |
| June 30, 2022 | 5.041M |
| March 31, 2021 | 4.554M |
| March 31, 2020 | 2.376M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.376M
Minimum
Mar 2020
7.264M
Maximum
Sep 2023
4.902M
Average
4.768M
Median
Research and Development Expense (Quarterly) Benchmarks
| Immuneering Corp | 11.20M |
| Outlook Therapeutics Inc | 4.529M |
| Amylyx Pharmaceuticals Inc | 36.61M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |